Candel Therapeutics, INC. (CADL) — SEC Filings

Overview

Candel Therapeutics, INC. (CADL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: Candel Therapeutics, Inc. filed an 8-K on December 5, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific details about the nature of the disclosure or the financial statements.

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 38 neutral, 2 mixed. The dominant filing sentiment for Candel Therapeutics, INC. is neutral.

Filing Type Overview

Candel Therapeutics, INC. (CADL) has filed 1 4, 27 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G, 1 10-K/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (40)

• 4 Filing — 4 · Apr 2, 2026
• Candel Therapeutics Files 8-K — 8-K · Dec 5, 2025 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on December 5, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
• Candel Therapeutics Narrows Loss Amid R&D Spend, Cash Burn Continues — 10-Q · Nov 13, 2025 Risk: high
  Candel Therapeutics, Inc. (CADL) reported a net loss of $8.686 million for the nine months ended September 30, 2025, a significant improvement from the $41.104
• Candel Therapeutics Files 8-K with Material Agreements and Financial Updates — 8-K · Oct 14, 2025 Risk: medium
  On October 14, 2025, Candel Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, repor
• Candel Therapeutics Enters Material Definitive Agreement — 8-K · Aug 21, 2025 Risk: medium
  Candel Therapeutics, Inc. announced on August 18, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of t
• CADL Swings to Profit on Warrant Revaluation, Boosts Capital — 10-Q · Aug 14, 2025 Risk: high
  Candel Therapeutics, Inc. (CADL) reported a net income of $2.583 million for the six months ended June 30, 2025, a significant improvement from a net loss of $3
• Candel Therapeutics Files 8-K: Material Agreement — 8-K · Jun 24, 2025 Risk: medium
  On June 23, 2025, Candel Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statem
• Candel Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jun 23, 2025 Risk: medium
  Candel Therapeutics, Inc. filed an 8-K on June 23, 2025, reporting events as of June 20, 2025. The filing indicates changes related to the departure of director
• Candel Therapeutics Reports on Shareholder Vote Outcomes — 8-K · Jun 18, 2025 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of its security holders on June 17, 2025. The filing details t
• Candel Therapeutics Reports Officer/Director Changes — 8-K · Jun 6, 2025 Risk: medium
  Candel Therapeutics, Inc. filed an 8-K on June 6, 2025, reporting events as of June 4, 2025. The filing indicates changes related to the departure of directors
• Candel Therapeutics Files 8-K Report — 8-K · May 28, 2025 Risk: low
  On May 28, 2025, Candel Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a R
• Candel Therapeutics Files 8-K — 8-K · May 22, 2025 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing d
• Candel Therapeutics Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  Candel Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its activities, including its At-The-Market Offering from
• Candel Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  Candel Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting on June 17, 2025. The filing outlines the com
• Candel Therapeutics Files 8-K — 8-K · Apr 23, 2025 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on April 23, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
• Candel Therapeutics Files 8-K — 8-K · Mar 27, 2025 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting events as of March 26, 2025. The filing includes information related to Regulation FD Disclo
• Candel Therapeutics Files 2024 10-K — 10-K · Mar 13, 2025 Risk: medium
  Candel Therapeutics, Inc. filed its 2024 10-K on March 13, 2025, reporting its fiscal year ended December 31, 2024. The company, focused on biological products,
• Candel Therapeutics Files 8-K — 8-K · Feb 25, 2025 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures,
• Candel Therapeutics Files 8-K on Financials and Operations — 8-K · Jan 13, 2025 Risk: medium
  Candel Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures
• SC 13G Filing — SC 13G · Dec 17, 2024
• Candel Therapeutics Files 8-K: Material Agreement and Other Events — 8-K · Dec 13, 2024 Risk: medium
  On December 12, 2024, Candel Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial stateme
• Candel Therapeutics Files 8-K — 8-K · Dec 11, 2024 Risk: medium
  Candel Therapeutics, Inc. filed an 8-K on December 11, 2024, to report on various events. The filing includes information related to Regulation FD Disclosure, O
• Candel Therapeutics Q3 2024 Update — 10-Q · Nov 14, 2024 Risk: medium
  Candel Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter
• Candel Therapeutics Files 8-K — 8-K · Oct 28, 2024 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on October 28, 2024, reporting on financial statements and exhibits, along with other events and a Regulation FD disclosu
• Candel Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Candel Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position and business operations. Key agreem
• Candel Therapeutics Reports Shareholder Vote — 8-K · Jun 28, 2024 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on June 28, 2024, reporting on a matter submitted to a vote of its security holders on June 26, 2024. The filing does not
• Candel Therapeutics Files Proxy Statement for Annual Meeting — DEF 14A · May 30, 2024 Risk: medium
  Candel Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on May 30, 2024, for its annual meeting of stockholders scheduled for June 26, 2024. The
• Candel Therapeutics Files 8-K with Corporate Updates — 8-K · May 30, 2024 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on May 29, 2024, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhi
• Candel Therapeutics Files 8-K — 8-K · May 23, 2024 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on May 23, 2024, to report on other events and financial statements. The filing does not contain specific details about n
• Candel Therapeutics, Inc. Files 10-Q for Q1 2024 — 10-Q · May 14, 2024 Risk: medium
  Candel Therapeutics, Inc. (CADL) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Candel Therapeutics, Inc. filed a 10-Q report for the period endi
• Candel Therapeutics Files 10-K/A Amendment for Fiscal Year Ended December 31, 2023 — 10-K/A · Apr 25, 2024 Risk: low
  Candel Therapeutics, Inc. (CADL) filed a Amended Annual Report (10-K/A) with the SEC on April 25, 2024. Candel Therapeutics, Inc. filed an amended 10-K report f
• Candel Therapeutics Files 8-K — 8-K · Apr 25, 2024 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on April 25, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
• Candel Therapeutics Partners with Bristol Myers Squibb for Cancer Trial — 8-K · Apr 11, 2024 Risk: medium
  Candel Therapeutics, Inc. announced on April 11, 2024, that it has entered into a clinical trial collaboration with Bristol Myers Squibb. This collaboration wil
• Candel Therapeutics Files 8-K — 8-K · Apr 9, 2024 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on April 9, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, othe
• Candel Therapeutics Partners with Bristol Myers Squibb for Melanoma Trial — 8-K · Apr 4, 2024 Risk: medium
  Candel Therapeutics, Inc. announced on April 4, 2024, that it has entered into a clinical trial collaboration with Bristol Myers Squibb. This collaboration will
• Candel Therapeutics, Inc. Files 2023 Annual Report (10-K) — 10-K · Mar 28, 2024 Risk: medium
  Candel Therapeutics, Inc. (CADL) filed a Annual Report (10-K) with the SEC on March 28, 2024. Candel Therapeutics, Inc. filed its 10-K report for the fiscal yea
• Candel Therapeutics Files 8-K for Regulatory and Financial Updates — 8-K · Mar 6, 2024 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on March 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
• Candel Therapeutics Files 8-K on Feb 13, Details Undisclosed — 8-K · Feb 13, 2024 Risk: low
  Candel Therapeutics, Inc. filed an 8-K on February 13, 2024, reporting on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The fil
• Candel Therapeutics Amends Officer Compensation on Jan 12 — 8-K · Jan 12, 2024
  Candel Therapeutics, Inc. (CADL) announced on January 12, 2024, that it has entered into new compensatory arrangements with certain officers. This 8-K filing, u
• Candel Therapeutics Confirms Emerging Growth Status in 8-K Filing — 8-K · Jan 3, 2024
  Candel Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an "Other Event" that occurred on December 28, 2023. This filing indicates that the company

Risk Profile

Risk Assessment: Of CADL's 36 recent filings, 2 were flagged as high-risk, 17 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Candel Therapeutics, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $0
• Net Income: -$8.686M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $86.963M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Industry Context

Candel Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on developing novel oncolytic immunotherapy candidates. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on the efficacy and safety of product candidates, as well as the ability to secure substantial funding for clinical trials and eventual commercialization.

Top Tags

8-K (7) · financials (7) · disclosure (6) · corporate-governance (5) · Biotechnology (4) · 10-Q (4) · biotech (4) · regulatory-filing (3) · filing (3) · SEC Filing (3)

Key Numbers

• Net Loss: $8.686M — For the nine months ended September 30, 2025, a significant improvement from $41.104M in 2024.
• Change in Fair Value of Warrant Liability: $21.718M — Positive impact on net loss for the nine months ended September 30, 2025.
• Research and Development Expenses: $19.468M — Increased from $14.497M in 2024 for the nine months ended September 30, 2025, reflecting pipeline investment.
• Net Cash Used in Operating Activities: $27.743M — For the nine months ended September 30, 2025, indicating ongoing cash burn.
• Cash and Cash Equivalents: $86.963M — As of September 30, 2025, down from $102.654M at December 31, 2024.
• Common Stock Shares Outstanding: 54,898,303 — As of November 5, 2025, indicating potential for further dilution.
• Proceeds from Registered Direct Offering: $14.331M — Contributed to financing activities for the nine months ended September 30, 2025.
• Net Income: $2.583M — For six months ended June 30, 2025, a significant improvement from a $30.458M net loss in H1 2024.
• Proceeds from At-the-Market Offerings: $5.038M — Additional capital raised during the six months ended June 30, 2025.
• Common Shares Outstanding: 54,895,099 — As of August 5, 2025, indicating dilution from capital raises.
• Accumulated Deficit: $189.622M — As of June 30, 2025, reflecting historical losses despite the recent net income.
• Reporting Period End Date: 20250331 — Indicates the end of the fiscal quarter covered by the report.
• At-The-Market Offering Period: 2025-01-01 to 2025-03-31 — Specifies the timeframe during which the company may have issued stock.
• Fiscal Year End: 2024-12-31 — Reporting period for the 10-K
• Filing Date: 2025-03-13 — Date the 10-K was submitted to the SEC

Related Companies

BMY

Frequently Asked Questions